BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22178962)

  • 21. Relative importance of CD4+ and CD8+ T cell repertoires in the development of acute graft-versus-host disease in a murine model of bone marrow transplantation.
    Miconnet I; de La Selle V; Bruley-Rosset M
    Bone Marrow Transplant; 1998 Mar; 21(6):583-90. PubMed ID: 9543062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of immunodominance among minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation.
    Mori S; El-Baki H; Mullen CA
    Bone Marrow Transplant; 2003 May; 31(10):865-75. PubMed ID: 12748663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies of immunologic tolerance to host minor histocompatibility antigens following allogeneic bone marrow transplantation in mice.
    Perreault C; Allard A; Brochu S; Poupart C; Fontaine P; Bélanger R; Gyger M
    Bone Marrow Transplant; 1990 Aug; 6(2):127-35. PubMed ID: 2145050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effects of various T cell subtypes on GVHD in a murine model for MHC-matched unrelated donor transplant.
    OKunewick JP; Kociban DL; Buffo MJ
    Bone Marrow Transplant; 1990 Mar; 5(3):145-52. PubMed ID: 1691938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.
    Ohashi M; Kobayashi A; Hara H; Miura Y; Yoshida K; Kushida M; Ikarashi Y; Mandai M; Kitajima M; Yoshida T; Aoki K
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2208-15. PubMed ID: 16609036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of donor and recipient gender disparities on fatal graft-vs.-host disease in a mouse model for major histocompatibility complex-matched unrelated-donor bone marrow transplantation.
    OKunewick JP; Kociban DL; Machen LL; Buffo MJ
    Exp Hematol; 1993 Nov; 21(12):1570-6. PubMed ID: 8405238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
    Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
    Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II.
    van Balen P; van Bergen CAM; van Luxemburg-Heijs SAP; de Klerk W; van Egmond EHM; Veld SAJ; Halkes CJM; Zwaginga JJ; Griffioen M; Jedema I; Falkenburg JHF
    Front Immunol; 2018; 9():3016. PubMed ID: 30619360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oligoclonal expansion of CTLs directed against a restricted number of dominant minor histocompatibility antigens in hemopoietic chimeras.
    Brochu S; Baron C; Hétu F; Roy DC; Perreault C
    J Immunol; 1995 Dec; 155(11):5104-14. PubMed ID: 7594519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of graft-versus-host disease by a novel immunosuppressant, (5R)-5-hydroxytriptolide (LLDT-8), through expansion of regulatory T cells.
    Tang W; Yang Y; Zhang F; Li YC; Zhou R; Wang JX; Zhu YN; Li XY; Yang YF; Zuo JP
    Int Immunopharmacol; 2005 Dec; 5(13-14):1904-13. PubMed ID: 16275625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of MHC II-restricted minor histocompatibility antigens after HLA-identical stem-cell transplantation.
    Milosevic S; Bachnick B; Karim K; Bornkamm GW; Witter K; Gerbitz A; Mautner J; Behrends U
    Transplantation; 2010 Nov; 90(9):1030-5. PubMed ID: 20802400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
    J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model.
    Jones SC; Murphy GF; Friedman TM; Korngold R
    J Clin Invest; 2003 Dec; 112(12):1880-6. PubMed ID: 14679183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A two-phase pathogenesis of graft-versus-host disease in mice.
    van Leeuwen L; Guiffre A; Atkinson K; Rainer SP; Sewell WA
    Bone Marrow Transplant; 2002 Jan; 29(2):151-8. PubMed ID: 11850710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation.
    Goulmy E; Schipper R; Pool J; Blokland E; Falkenburg JH; Vossen J; Gratwohl A; Vogelsang GB; van Houwelingen HC; van Rood JJ
    N Engl J Med; 1996 Feb; 334(5):281-5. PubMed ID: 8532022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.
    Blazar BR; Taylor PA; Snover DC; Bluestone JA; Vallera DA
    J Immunol; 1993 Jan; 150(1):265-77. PubMed ID: 8417127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.
    Sykes M; Abraham VS; Harty MW; Pearson DA
    J Immunol; 1993 Jan; 150(1):197-205. PubMed ID: 8093257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.